Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Lyka Labs's Enterprise Value is ₹3,020 Mil.
Lyka Labs's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-86 Mil. Therefore, Lyka Labs's EV-to-EBIT ratio for today is -35.04.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Lyka Labs's Enterprise Value is ₹3,020 Mil.
Lyka Labs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-2 Mil. Therefore, Lyka Labs's EV-to-EBITDA ratio for today is -1,895.74.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Lyka Labs's Enterprise Value is ₹3,020 Mil.
Lyka Labs's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,284 Mil. Therefore, Lyka Labs's EV-to-Revenue ratio for today is 2.35.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Lyka Labs's Enterprise Value is ₹3,020 Mil.
Lyka Labs's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Lyka Labs's EV-to-FCF ratio for today is .
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Lyka Labs (BOM:500259) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Lyka Labs's current Enterprise Value is ₹3,020 Mil.
Lyka Labs's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-86 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Lyka Labs's current Enterprise Value is ₹3,020 Mil.
Lyka Labs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-2 Mil.
Lyka Labs's current Enterprise Value is ₹3,020 Mil.
Lyka Labs's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,284 Mil.
Lyka Labs's current Enterprise Value is ₹3,020 Mil.
Lyka Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
Lyka Labs's current Enterprise Value is ₹3,020 Mil.
Lyka Labs's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyka Labs Enterprise Value Related Terms
Lyka Labs Enterprise Value Historical Data
* Premium members only.
The historical data trend for Lyka Labs's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500259 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Lyka Labs's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyka Labs Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyka Labs's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Lyka Labs's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Lyka Labs's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyka Labs (BOM:500259) has a Enterprise Value of ₹3,020 Mil as of Jul. 12, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Lyka Labs and its competitors.
Is Lyka Labs' Enterprise Value too high?
Lyka Labs' current Enterprise Value is ₹3,020 Mil. Overall, Lyka Labs has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' Enterprise Value compare to VRTX and REGN?
Lyka Labs' Enterprise Value of ₹3,020 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Lyka Labs and its competitors. Lyka Labs's current Enterprise Value is ₹3,020 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹127.26, compared to a current price of ₹72.36 — trading 43.1% below its estimated fair value. The current Enterprise Value is ₹3,020 Mil. Lyka Labs' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current Enterprise Value is ₹3,020 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyka Labs (BOM:500259) Overvalued in 2026?
Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued.
The current stock price of ₹72.36 is trading 43.1% below its estimated GF Value™ of ₹127.26.
GuruFocus considers Lyka Labs to be Significantly Undervalued.
Key valuation signals for BOM:500259:
Enterprise Value: ₹3,020 Mil
GF Value™: ₹127.26 vs. price of ₹72.36 (43.1% below fair value)
No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
60GF Score
Get the complete analysis for BOM:500259
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500259 has been successfully added to your 
